Phreesia: Solid Operating Leverage but Regulatory Headwinds and Slowing Life Sciences Growth Warrant Hold Rating

In a report released today, Daniel Grosslight from Citi downgraded Phreesia to a Hold, with a price target of $10.00.

Daniel Grosslight has given his Hold rating due to a combination of factors related to Phreesia’s near‑term growth outlook and valuation. He sees the company’s plan to boost revenue per healthcare customer through its life sciences (NS) segment running into macro and regulatory headwinds, notably weaker pharma advertising demand in vaccines, public health, and GLP‑1 categories. Phreesia cut its revenue outlook by a sizable amount concentrated in this NS business, now projecting only modest overall enterprise growth with very limited underlying organic expansion.

At the same time, Grosslight acknowledges that Phreesia continues to demonstrate solid operating leverage, as evidenced by maintaining its adjusted EBITDA guidance despite the revenue reset, which supports some downside protection. However, he believes the lack of visibility on when NS growth will reaccelerate, combined with dependence on improving direct‑to‑consumer ad spend and early‑stage products such as AccessOne and HCP advertising, justifies a more cautious stance. His $10 target price, based on a discounted EBITDA multiple versus peers, reflects the view that the shares are likely to trade in a range until clearer signs of renewed growth emerge.

Grosslight covers the Healthcare sector, focusing on stocks such as Teladoc, GoodRx Holdings, and Hims & Hers Health. According to TipRanks, Grosslight has an average return of 1.2% and a 43.62% success rate on recommended stocks.

In another report released today, Robert W. Baird also downgraded the stock to a Hold with a $10.00 price target.